<?xml version="1.0" encoding="UTF-8" standalone="yes"?>
<References xsi:schemaLocation="http://www.iedb.org/schema/CurationSchema http://beta.iedb.org/schema/Curation.xsd" xmlns="http://www.iedb.org/schema/CurationSchema" xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance">
    <Reference>
        <ReferenceId>1097</ReferenceId>
        <DateLastUpdated>2020-09-10-07:00</DateLastUpdated>
        <Article>
            <PubmedId>15016861</PubmedId>
            <Abstract>Site-directed photoaffinity cross-linking experiments were performed by using human immunodeficiency virus type 1 (HIV-1) reverse transcriptase (RT) mutants with unique cysteine residues at several positions (i.e., positions 65, 67, 70, and 74) in the fingers subdomain of the p66 subunit. Since neither the introduction of the unique cysteine residues into the fingers nor the modification of the SH groups of these residues with photoaffinity cross-linking reagents caused a significant decrease in the enzymatic activities of RT, we were able to use this system to measure distances between specific positions in the fingers domain of RT and double-stranded DNA. HIV-1 RT is quite flexible. There are conformational changes associated with binding of the normal substrates and nonnucleoside RT inhibitors (NNRTIs). Cross-linking was used to monitor intramolecular movements associated with binding of an NNRTI either in the presence or in the absence of an incoming deoxynucleoside triphosphate (dNTP). Binding an incoming dNTP at the polymerase active site decreased the efficiency of cross-linking but caused only modest changes in the preferred positions of cross-linking. This finding suggests that the fingers of p66 are closer to an extended template in the "open" configuration of the enzyme with the fingers away from the active site than in the closed configuration with the fingers in direct contact with the incoming dNTP. NNRTI binding caused increased cross-linking in experiments with diazirine reagents (especially with a diazirine reagent with a longer linker) and a moderate shift in the preferred sites of interaction with the template. Cross-linking occurred closer to the polymerase active site for RTs modified at positions 70 and 74. The effects of NNRTI binding were more pronounced in the absence of a bound dNTP; pretreatment of HIV-1 RT with an NNRTI reduced the effect of dNTP binding. These observations can be explained if the binding of NNRTI causes a decrease in the flexibility in the fingers subdomain of RT-NNRTI complex and a decrease in the distance from the fingers to the template extension.</Abstract>
            <ArticleYear>2004</ArticleYear>
            <ArticlePages>3387-97</ArticlePages>
            <ArticleTitle>Nonnucleoside inhibitor binding affects the interactions of the fingers subdomain of human immunodeficiency virus type 1 reverse transcriptase with DNA.</ArticleTitle>
            <Authors>
                <Author>
                    <LastName>Peletskaya</LastName>
                    <ForeName>Elena N</ForeName>
                </Author>
                <Author>
                    <LastName>Kogon</LastName>
                    <ForeName>Alex A</ForeName>
                </Author>
                <Author>
                    <LastName>Tuske</LastName>
                    <ForeName>Steven</ForeName>
                </Author>
                <Author>
                    <LastName>Arnold</LastName>
                    <ForeName>Edward</ForeName>
                </Author>
                <Author>
                    <LastName>Hughes</LastName>
                    <ForeName>Stephen H</ForeName>
                </Author>
            </Authors>
            <Affiliations>HIV Drug Resistance Program. SAIC Frederick, National Cancer Institute at Frederick, Frederick, Maryland 21702-1201, USA.</Affiliations>
            <ArticleChemicalList>Cross-Linking Reagents;Recombinant Proteins;Reverse Transcriptase Inhibitors;DNA;HIV Reverse Transcriptase;Cysteine</ArticleChemicalList>
            <ArticleMeshHeadingsList>Amino Acid Substitution(genetics); Binding Sites; Cross-Linking Reagents(chemistry; metabolism); Cysteine(genetics; metabolism); DNA(metabolism); Escherichia coli; HIV Reverse Transcriptase(antagonists &amp; inhibitors; chemistry; genetics; metabolism); HIV-1(enzymology; genetics); Models, Molecular; Photochemistry; Protein Binding(drug effects); Protein Structure, Tertiary; Recombinant Proteins(antagonists &amp; inhibitors; chemistry; genetics; metabolism); Reverse Transcriptase Inhibitors(chemistry; metabolism; pharmacology)</ArticleMeshHeadingsList>
            <Journal>
                <Volume>78</Volume>
                <Issue>7</Issue>
                <Title>Journal of virology</Title>
                <Issn>1098-5514</Issn>
                <MedlineTa>J Virol</MedlineTa>
            </Journal>
        </Article>
        <Epitopes>
            <Epitope>
                <EpitopeName>Epitope of Fab on HIV-1 RT</EpitopeName>
                <EpitopeStructure>
                    <DiscontinuousRegionOnAccessionSequenceMolecule>
                        <ChemicalType>Discontinuous protein residues</ChemicalType>
                        <DiscontinuousResidues>R199, H221, Q222, K223, E224, P225, P226, F227, W229, M230, R358</DiscontinuousResidues>
                        <SourceMolecule>
                            <GenBankId>NP_789739.1</GenBankId>
                        </SourceMolecule>
                        <SourceOrganismId>11676</SourceOrganismId>
                    </DiscontinuousRegionOnAccessionSequenceMolecule>
                </EpitopeStructure>
                <LocationOfData>PDB 1R0A</LocationOfData>
                <EpitopeId>150954</EpitopeId>
                <ReferenceRegion>R199, H221, Q222, K223, E224, P225, P226, F227, W229, M230, R358</ReferenceRegion>
                <EpitopeEvidenceCode>Representative selection</EpitopeEvidenceCode>
                <EpitopeStructureDefines>Exact Epitope</EpitopeStructureDefines>
                <EpitopeComments>Epitope residues are calculated from the PDB structure [PDB: 1R0A] as the antigen residues at 4 Ã… atomic distance from the antibody.</EpitopeComments>
                <Assays>
                    <BCell>
                        <LocationOfData>Figure 1 and PDB 1R0A</LocationOfData>
                        <BCellId>1838738</BCellId>
                        <Immunization>
                            <HostOrganism>
                                <OrganismId>10000000</OrganismId>
                                <Age>8 weeks</Age>
                            </HostOrganism>
                            <FirstInVivoProcess>
                                <InVivoProcessType>Administration in vivo</InVivoProcessType>
                                <ImmunogenObject>
                                    <EpitopeRelation>Source Antigen</EpitopeRelation>
                                    <Object>
                                        <AccessionSequenceMolecule>
                                            <ChemicalType>Protein</ChemicalType>
                                            <Molecule>
                                                <GenBankId>NP_789739.1</GenBankId>
                                            </Molecule>
                                            <SourceOrganismId>11676</SourceOrganismId>
                                        </AccessionSequenceMolecule>
                                    </Object>
                                </ImmunogenObject>
                                <ImmunogenReferenceName>HIV-1 RT (66 kDa form)</ImmunogenReferenceName>
                                <ImmunogenEvidenceCode>Representative selection</ImmunogenEvidenceCode>
                                <Adjuvant>Freund's complete</Adjuvant>
                                <Adjuvant>Freund's incomplete (IFA)</Adjuvant>
                                <Route>Intraperitoneal (i.p.)</Route>
                                <DoseSchedule>2 doses at a 2-wk interval and 1 dose 4 days before cell fusion</DoseSchedule>
                            </FirstInVivoProcess>
                            <ImmunizationComments>Generation of the monoclonal antibody was previously described in the reference: Ferris et al. (1990) Virology 175(2): 456-464 [PMID: 1691562]. Mice were immunized with purified RT (66 kDa form).</ImmunizationComments>
                        </Immunization>
                        <AssayInformation>
                            <AssayTypeId>436</AssayTypeId>
                            <QualitativeMeasurement>Positive</QualitativeMeasurement>
                            <QuantitativeMeasurement>2.8</QuantitativeMeasurement>
                            <MeasurementInequality>=</MeasurementInequality>
                            <AssayComments>The epitope of Fab28 on the HIV-1 RT p51 subunit was determined from the crystal structure of Fab28 bound to the complex of HIV-1 RT p51/p66 dimer covalently tethered to DNA template-primer (27-mer/21-mer). Fab28 binds to the p51 palm subdomain and has no contacts with either the p66 subunit or the DNA. The HIV-1 RT p51 subunit contained the C280S mutation.</AssayComments>
                        </AssayInformation>
                        <AssayedAntibody>
                            <AssayedAntibodySourceMaterial>Purified Immunoglobulin</AssayedAntibodySourceMaterial>
                            <AssayedAntibodyImmunoglobulinDomain>Fab</AssayedAntibodyImmunoglobulinDomain>
                            <AssayedAntibodyPurificationStatus>Monoclonal</AssayedAntibodyPurificationStatus>
                            <AssayedAntibodyName>Fab28</AssayedAntibodyName>
                            <AssayedAntibodyHeavyChainType>IgG1</AssayedAntibodyHeavyChainType>
                            <AssayedAntibodyLightChainType>Kappa</AssayedAntibodyLightChainType>
                            <AssayedAntibodyObject>
                                <MultiChainMolecule>
                                    <ChemicalType>Multi-Chain protein</ChemicalType>
                                    <MoleculeName>Fab28</MoleculeName>
                                    <Chain1>
                                        <Molecule>
                                            <GenBankId>1T03_H</GenBankId>
                                        </Molecule>
                                        <SourceOrganismId>10090</SourceOrganismId>
                                    </Chain1>
                                    <Chain2>
                                        <Molecule>
                                            <GenBankId>1T03_L</GenBankId>
                                        </Molecule>
                                        <SourceOrganismId>10090</SourceOrganismId>
                                    </Chain2>
                                </MultiChainMolecule>
                            </AssayedAntibodyObject>
                        </AssayedAntibody>
                        <Antigen>
                            <AntigenReferenceName>HIV-1 RT p51/p66 dimer/DNA</AntigenReferenceName>
                            <AntigenConformation>Native</AntigenConformation>
                            <AntigenObject>
                                <EpitopeRelation>Source Antigen</EpitopeRelation>
                                <Object>
                                    <AccessionSequenceMolecule>
                                        <ChemicalType>Protein</ChemicalType>
                                        <Molecule>
                                            <GenBankId>NP_789739.1</GenBankId>
                                        </Molecule>
                                        <SourceOrganismId>11676</SourceOrganismId>
                                    </AccessionSequenceMolecule>
                                </Object>
                            </AntigenObject>
                            <AntigenEvidenceCode>Representative selection</AntigenEvidenceCode>
                            <AntigenContainingObject>
                                <ComplexedMolecule>
                                    <ComplexType>Protein conjugate</ComplexType>
                                    <PeptideModifications/>
                                    <SourceMolecule>
                                        <GenBankId>YP_001856242.1</GenBankId>
                                    </SourceMolecule>
                                    <MoleculeSourceOrganismId>11676</MoleculeSourceOrganismId>
                                </ComplexedMolecule>
                            </AntigenContainingObject>
                        </Antigen>
                        <ThreeDimensionalStructureOfComplex>
                            <ComplexPdbId>1R0A</ComplexPdbId>
                            <AntibodyChain1PdbChain>H</AntibodyChain1PdbChain>
                            <AntibodyChain2PdbChain>L</AntibodyChain2PdbChain>
                            <AntigenChainPdbChain>B</AntigenChainPdbChain>
                            <ViewerFlag>Y</ViewerFlag>
                            <CuratedContacts>
                                <EpitopeResidues>B: ;</EpitopeResidues>
                                <AntibodyResiduesInteractingWithAntigen>H: ; L: ;</AntibodyResiduesInteractingWithAntigen>
                            </CuratedContacts>
                            <CalculatedContacts>
                                <EpitopeResidues>B: R199, H221, Q222, K223, E224, P225, P226, F227, W229, M230, R358</EpitopeResidues>
                                <AntibodyResiduesInteractingWithAntigen>H: S32, G33, W54, W55, D56, D58, R60, I102, T103, S104, V105, T106, S108; L: Y32, Y91, S92, K93, F94</AntibodyResiduesInteractingWithAntigen>
                                <ContactAreaForAntigen>712.5</ContactAreaForAntigen>
                                <ContactAreaForAntibody>619.3</ContactAreaForAntibody>
                            </CalculatedContacts>
                        </ThreeDimensionalStructureOfComplex>
                    </BCell>
                </Assays>
            </Epitope>
        </Epitopes>
    </Reference>
</References>

